Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Institute of Cancer Research · Radboud University Nijmegen · +19 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
559
total citations
- FWCI
- 21.38
- Percentile
- 100%
- References
- 25
Citations per year
Authors
17- UBUdai BanerjiCorresponding
Institute of Cancer Research
- CMCarla M.L. van Herpen
Radboud University Nijmegen, Radboud University Medical Center
- CSCristina Saura
Vall d'Hebron Institute of Oncology, Vall d'Hebron Hospital Universitari
- FTFiona Thistlethwaite
The Christie NHS Foundation Trust, University of Manchester
- SLSimon Lord
Churchill Hospital
Topics & keywords
Topics
Keywords
- Medicine
- Trastuzumab
- Clinical endpoint
- Response Evaluation Criteria in Solid Tumors
- Metastatic breast cancer
- Oncology
- Internal medicine
- Breast cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.